# Anticoagulation

Anticoagulation – Madeleine Turcotte

| 0                      | 1                                                      | 2                                        | 3                        | 4                                                                         |
|------------------------|--------------------------------------------------------|------------------------------------------|--------------------------|---------------------------------------------------------------------------|
| Agent                  | Dose                                                   | Renal Dose                               | Prophylaxis              | Monitoring                                                                |
| Unfractionated heparin | 80 U/kg bolus, then 18 U/kg/hr                         | No change necessary                      | 5000 U q8 hr             | PTT (automatic in order set)                                              |
| Enoxaparin (Lovenox)   | 1 mg/kg q 12 hr                                        | 1 mg/kg daily                            | 40 mg daily or 30 mg BID | LMWH level (anti-Xa level) Best checked 4 hr after 4th dose               |
| Warfarin (Coumadin)    | Start 2-5mg daily and monitor INR Can consult Pharmacy | No change necessary                      | NaN                      | PT/INR Use Chromogenic Factor X assay if pt has APLS                      |
| Dabigatran (Pradaxa)   | After 5 days of a parenteral AC, 150 mg BID            | Avoid use                                | NaN                      | Can test drug level if concerned (Any DOAC)                               |
| Rivaroxaban (Xarelto)  | 15 mg BID x21 d then 20 mg daily                       | Avoid use in CrCl\<30                    | 10mg QD                  | NaN                                                                       |
| Apixaban (Eliquis)     | 10mg BID x7d, then 5mg BID                             | VTE: No adjustment                       | 2.5 mg BID               | A Fib: 2.5mg BID, if 2 of the following: Cr 1.5, Age \> 80 Weight \< 60kg |
| Edoxaban (Savaysa)     | After 5 days of a parenteral AC, 60 mg daily           | 30 mg for CrCl 15-50 Avoid if CrCl \> 95 | NaN                      | Best studied option in renal dysfunction                                  |

| 0                                             | 1                                           |
|-----------------------------------------------|---------------------------------------------|
| NOAC/DOAC                                     | Warfarin                                    |
| Quick onset/offset, fixed dosing              | Antidote/reversal agent available           |
| Reduced incidence of hemorrhagic stroke       | Measurable levels of anticoagulation effect |
| Fewer drug interactions, no food interaction  | Strongest evidence in patients with ESRD    |
| No need for routine monitoring                | Lower risk of GI bleeding (varies)          |
| Monthly cost $350-450 but discounts available | Monthly cost: $4                            |

Additional Information

-   VA favors dabigatran among DOACs
    -   Dabigatran cannot be stored in a pill box
    -   PADR for apixaban citing “patient uses a pillbox and cannot use
        dabigatran”
-   Concomitant Malignancy: favor LMWH, can also use apixaban
-   Renal dysfunction: favor warfarin, apixaban or edoxaban
-   Hx of GI bleed: avoid dabigatran, rivaroxaban, edoxaban (may have
    higher risk of GI bleed)
-   Pregnancy: LMWH (other agents may cross the placenta)

| 0                         | 1                                                                                                                                                                                 | 2                                                                                                                                                            |
|---------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indication                | Agent / Duration                                                                                                                                                                  | Other Notes                                                                                                                                                  |
| VTE                       | Any agent Duration: See VTE section                                                                                                                                               | See Deciding between Agents                                                                                                                                  |
| Atrial Fib (non-valvular) | Apixaban or dabigatran Duration: Indefinite CHADSVASc \> 2, Consider if score of 1                                                                                                | All DOACs: ↓ rates of ICH Apixaban & dabigatran: superior to warfarin in preventing stroke                                                                   |
| Artificial Heart Valves   | Warfarin Target INR depends on type of valve If the pt has concurrent Afib, may need higher INR goal Duration: Mechanical, Indefinite Surgically placed bioprosthetic, 3-6 months | DOACs contraindicated with mechanical valves! Bioprosthetic valves: DOACs okay if coexisting indication No AC after TAVR unless patient has other indication |
| ACS                       | PCI: Heparin or LMWH until PCI Fibrinolytic: 2-8 days after fibrinolysis                                                                                                          | If other indication for AC, assess bleeding/thrombosis risks to determine AC/Antiplatelet combination                                                        |
| ACS                       | No PCI: rivaroxaban 2.5 mg BID for 1 year, then reassess risk/benefit                                                                                                             | If other indication for AC, assess bleeding/thrombosis risks to determine AC/Antiplatelet combination                                                        |
| LV Thrombus               | Warfarin superior Duration: At least 3 months                                                                                                                                     | AC can also be considered in patients with MI who are at high risk for LV thrombus: LVEF \<30% w/ antero-apical wall motion abnormalities                    |
| Portal Vein Thrombus      | Any agent DOAC preferred In cirrhosis (INR may not reflect level of anticoagulation) Duration: 3-6 months, or indefinitely if pt has permanent thrombotic risk factors            | Consider bleeding risk: large esophageal varices                                                                                                             |
| Thrombophilia             | Any agent (DOACs less effective in APS) Duration: 6 months after any thrombosis Lifelong if recurrent, life-threatening, or unprovoked                                            | Antiphospholipid antibody syndrome: lifelong warfarin for any thrombosis that is otherwise unprovoked                                                        |

Transitioning Between Anticoagulants with DOACs

-   LMWH
    to Warfarin
    -   Warfarin and LMWH given simultaneously until INR is therapeutic
        for 24 hours
-   Warfarin
    to DOAC
    -   Start
        DOAC when INR \< 2.0
-   DOAC
    to Warfarin
    -   High Risk DVT/PE – start LMWH or UFH, then start Warfarin
    -   Low to Moderate Risk DVT/PE – Start warfarin while patient on
        DOAC, Stop DOAC on Day 3 of warfarin therapy, Check INR on day 4
-   LMWH
    to DOAC
    -   Stop LMWH and start DOAC when due for next dose of LMWH (within
        2 hrs)
-   DOAC
    to LMWH
    -   Stop
        DOAC and start LMWH when due for next DOAC dose
-   UFH
    to DOAC
    -   Start
        DOAC when IV stopped (30 min prior to cessation if high risk for
        thrombosis)
    -   DOAC
        to UFH
    -   Start IV heparin with bolus when next DOAC dose is due

Peri-Procedural Management of Anticoagulation

-   Temporary IVC filter indicated in pts with very recent acute VTE
    (within 3-4 weeks) if the procedure requires AC delay >12 hours
-   For those at high risk of thromboembolism:
    -   Consider continuing AC for low-bleeding-risk procedures, i.e.
        dental procedures, cutaneous biopsy/excision, ICD placement,
        endovascular procedures.
    -   Can bridge with LMWH or heparin drip

| 0           | 1                                                                                      | 2                                                   |
|-------------|----------------------------------------------------------------------------------------|-----------------------------------------------------|
| NaN         | Stop before procedure                                                                  | Restart after procedure                             |
| Warfarin    | 5 days prior, check INR day of                                                         | 12 to 24 hours after                                |
| Dabigatran  | One day prior (2 days if CrCl 30-50 or procedure is high bleeding risk)                | 1 day after (2 days if high bleeding risk)          |
| Rivaroxaban | One day prior (2 days if CrCl 30-50 or procedure is high bleeding risk)                | 1 day after (2 days if high bleeding risk)          |
| Apixaban    | One day prior (2 days if CrCl 30-50 or procedure is high bleeding risk)                | 1 day after (2 days if high bleeding risk)          |
| Edoxaban    | One day prior (2 days if CrCl 30-50 or procedure is high bleeding risk)                | 1 day after (2 days if high bleeding risk)          |
| Heparin     | Stop infusion 4-5 hours prior                                                          | 24 hours after                                      |
| Enoxaparin  | 24 hours prior (hold evening dose if BID dosing, give half of AM dose if daily dosing) | 24 hours after, (48-72 hours if high bleeding risk) |

Strategies for Reversal of Anticoagulation

Warfarin

-   Vitamin
    K: onset at 12 hours but takes 24-48 hrs for full effect
    -   Life Threatening Bleeding: Give IV Vitamin K 10 mg over 30
        minutes
    -   Intracranial
        bleed, bleed with hemodynamic instability, emergent procedure
        Non-life threatening
        -   INR \<5: Vitamin K not recommended
        -   INR 5-10: Vitamin K 1-5 mg IV or PO
        -   INR >10: Vitamin K 5mg PO or 5 mg IV

<!-- -->

-   -   Prior to surgery
        -   Rapid reversal INR > 5: 5mg Vit K IV (24 hours prior to
            procedure)
    -   FFP
        -   15 ml/kg (i.e. 4 units/70 kg person) if need reversal \<24
            hrs, plus give Vitamin K
    -   KCentra ($$$): Contains Factors II, VII, IX, and X with Protein
        C, Protein S, and heparin
        -   Given instead of plasma when insufficient time for
            plasma/Vit K to work
        -   Avoid giving this in HIT
        -   Administer with Vitamin K

Dabigatran

-   Idarucizumab
    ($$$) will reverse if prolonged thrombin time – Consult Hematology

Xa

drugs

(Rivaroxaban, apixaban, edoxaban)

-   FEIBA
    (Factor VIII inhibitor bypassing activity) – can promote coagulation
    but is not a reversal agent; limited data to support use
-   Consult Hematology before using; andexanet alfa is not yet available
    here
